Xenon Pharmaceuticals (XENE) Accumulated Depreciation & Amortization (2013 - 2025)
Xenon Pharmaceuticals (XENE) reported Accumulated Depreciation & Amortization of -$7.4 million for Q4 2025, up 16.25% year-over-year from -$6.4 million in Q4 2024, and up 16.25% on a QoQ basis from -$8.8 million in Q4 2024.
Xenon Pharmaceuticals (XENE) has 13 years of Accumulated Depreciation & Amortization data on file, last reported at -$7.4 million in Q4 2025.
- Quarterly Accumulated Depreciation & Amortization rose 16.25% year-over-year to -$7.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.4 million (up 16.25% YoY) and the FY2025 annual result came in at -$7.4 million, up 16.25% from the prior year.
- Accumulated Depreciation & Amortization climbed to -$7.4 million in Q4 2025 per XENE's latest filing, from -$8.8 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $4.0 million in Q4 2021 and bottomed at -$8.8 million in Q4 2024.
- The 5-year median for Accumulated Depreciation & Amortization is -$7.4 million (2025), against an average of -$3.6 million.
- The widest annual swing landed in 2021, when Accumulated Depreciation & Amortization soared 39.56%; it then sank 437.22% in 2023.
- Tracing XENE's Accumulated Depreciation & Amortization over 5 years: stood at $4.0 million in 2021, then plunged by 38.83% to $2.4 million in 2022, then slumped by 437.22% to -$8.2 million in 2023, then slipped by 7.97% to -$8.8 million in 2024, then increased by 16.25% to -$7.4 million in 2025.
- Per Business Quant, the three latest XENE Accumulated Depreciation & Amortization figures stand at -$7.4 million (Q4 2025), -$8.8 million (Q4 2024), and -$8.2 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Xenon Pharmaceuticals | 4.78 Bn | 4.78 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.38 Mn |
| Dec 31, 2025 | -7.38 Mn |
| Dec 31, 2024 | -8.82 Mn |
| Dec 31, 2024 | -8.82 Mn |
| Dec 31, 2023 | -8.16 Mn |
| Dec 31, 2023 | -8.16 Mn |
| Dec 31, 2022 | 2.42 Mn |
| Dec 31, 2022 | 2.42 Mn |
| Dec 31, 2021 | 3.96 Mn |
| Dec 31, 2021 | 3.96 Mn |
| Dec 31, 2020 | 2.84 Mn |
| Dec 31, 2020 | 2.84 Mn |
| Dec 31, 2019 | 813,000.00 |
| Dec 31, 2019 | 813,000.00 |
| Dec 31, 2018 | 1.47 Mn |
| Dec 31, 2018 | 1.47 Mn |
| Dec 31, 2017 | -27,000.00 |
| Dec 31, 2017 | -27,000.00 |
| Dec 31, 2016 | 4.97 Mn |
| Dec 31, 2016 | 4.97 Mn |
| Dec 31, 2015 | 4.94 Mn |
| Dec 31, 2015 | 4.94 Mn |
| Dec 31, 2014 | 738,000.00 |
| Dec 31, 2014 | 738,000.00 |
| Dec 31, 2013 | 705,000.00 |
| Dec 31, 2013 | 705,000.00 |